| Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition H Salmon, J Idoyaga, A Rahman, M Leboeuf, R Remark, S Jordan, ... Immunity 44 (4), 924-938, 2016 | 1041 | 2016 |
| In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study JD Brody, WZ Ai, DK Czerwinski, JA Torchia, M Levy, RH Advani, YH Kim, ... Journal of clinical oncology 28 (28), 4324, 2010 | 519 | 2010 |
| Depleting tumor-specific Tregs at a single site eradicates disseminated tumors A Marabelle, H Kohrt, I Sagiv-Barfi, B Ajami, RC Axtell, G Zhou, ... The Journal of clinical investigation 123 (6), 2447-2463, 2013 | 450 | 2013 |
| Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells CA Dutertre, E Becht, SE Irac, A Khalilnezhad, V Narang, S Khalilnezhad, ... Immunity 51 (3), 573-589. e8, 2019 | 397 | 2019 |
| Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells J Reichel, A Chadburn, PG Rubinstein, L Giulino-Roth, W Tam, Y Liu, ... Blood, The Journal of the American Society of Hematology 125 (7), 1061-1072, 2015 | 352 | 2015 |
| Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination L Hammerich, TU Marron, R Upadhyay, J Svensson-Arvelund, ... Nature medicine 25 (5), 814-824, 2019 | 340 | 2019 |
| Tracing superior longitudinal fasciculus connectivity in the human brain using high resolution diffusion tensor tractography A Kamali, AE Flanders, J Brody, JV Hunter, KM Hasan Brain Structure and Function 219, 269-281, 2014 | 296 | 2014 |
| Cancer vaccines: the next immunotherapy frontier MJ Lin, J Svensson-Arvelund, GS Lubitz, A Marabelle, I Melero, BD Brown, ... Nature cancer 3 (8), 911-926, 2022 | 269 | 2022 |
| CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies HE Kohrt, R Houot, MJ Goldstein, K Weiskopf, AA Alizadeh, J Brody, ... Blood, The Journal of the American Society of Hematology 117 (8), 2423-2432, 2011 | 258 | 2011 |
| Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, ... Cancer discovery 10 (1), 40-53, 2020 | 241 | 2020 |
| In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study YH Kim, D Gratzinger, C Harrison, JD Brody, DK Czerwinski, WZ Ai, ... Blood, The Journal of the American Society of Hematology 119 (2), 355-363, 2012 | 224 | 2012 |
| Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study A Younes, J Brody, C Carpio, A Lopez-Guillermo, D Ben-Yehuda, ... The Lancet Haematology 6 (2), e67-e78, 2019 | 186 | 2019 |
| High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells JH Myklebust, JM Irish, J Brody, DK Czerwinski, R Houot, HE Kohrt, ... Blood, The Journal of the American Society of Hematology 121 (8), 1367-1376, 2013 | 186 | 2013 |
| In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf L Hammerich, A Binder, JD Brody Molecular oncology 9 (10), 1966-1981, 2015 | 183 | 2015 |
| Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab … KJ Harrington, J Brody, M Ingham, J Strauss, S Cemerski, M Wang, A Tse, ... Annals of Oncology 29, viii712, 2018 | 182 | 2018 |
| DC-SIGN+ macrophages control the induction of transplantation tolerance P Conde, M Rodriguez, W van der Touw, A Jimenez, M Burns, J Miller, ... Immunity 42 (6), 1143-1158, 2015 | 177 | 2015 |
| Combination strategies to enhance antitumor ADCC HE Kohrt, R Houot, A Marabelle, HJ Cho, K Osman, M Goldstein, R Levy, ... Immunotherapy 4 (5), 511-527, 2012 | 169 | 2012 |
| Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) A Marabelle, R Andtbacka, K Harrington, I Melero, R Leidner, T de Baere, ... Annals of Oncology 29 (11), 2163-2174, 2018 | 162 | 2018 |
| Pattern recognition receptors: immune targets to enhance cancer immunotherapy T Shekarian, S Valsesia-Wittmann, J Brody, MC Michallet, S Depil, ... Annals of Oncology 28 (8), 1756-1766, 2017 | 133 | 2017 |
| A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy R Upadhyay, JA Boiarsky, G Pantsulaia, J Svensson-Arvelund, MJ Lin, ... Cancer discovery 11 (3), 599-613, 2021 | 120 | 2021 |
Ronald LevyProfessor of Medicine, Stanford UniversityVerified email at stanford.edu
